What is new in the treatment of genitourinary (GU) cancer? Read our genitourinary cancer blog and learn more about the latest advancements in the treatment of testicular, urothelial (bladder), renal (kidney), and prostate cancer.

U.S. FDA Approved Immune-Checkpoint Inhibitors Updated 18-Jun-2018

Since 2011, when the United States Food and Drug Administration (U.S. FDA) approved ipilimumab (Yervoy®) for malignant melanoma, several immune-checkpoint inhibitors have been granted marketing authorisation. Do you know all the indications? MediPaper made an overview of all the U.S. FDA approved immune-checkpoint inhibitors and other U.S. FDA approved immunotherapies.

FDA safety alert: use of immunotherapy in metastatic urothelial cancer with low PD-L1 expression

On May 18, the United States (US) Food and Drug Administration (FDA) issued an alert about the decreased survival in studies with pembrolizumab (Keytruda®) and atezolizumab (Tecentriq®) as single agent first-line therapy for patients with metastatic urothelial cancer (mUCC) and low expression of the programmed death ligand 1 (PD-L1) protein.

manuela schmidinger sutent sunitinib ae management manuela schmidinger manuela schmidinger sutent sunitinib side-effect management sutent sunitinib toxicity management Sutent Sunitinib AE management toxicity management side-effect management sorafenib pazopanib axitinib regorafenib vandetanib cabozantinib lenvatinib bevacizumab VEGFR VEGF renal cell carcinoma RCC kidney cancer renal cell cancer schmidinger

Achieving Long-Term Survival in the First-Line Treatment of Metastatic Renal Cell Carcinoma; A Balancing Act of Efficacy and Side-Effects

There is no excerpt because this is a protected post.

Nivolumab Renal Cell Cancer Symposium Highlight

Nivolumab for Renal Carcinoma: Getting the Most Out of PD-1 Immunotherapy

There is no excerpt because this is a protected post.

PD-L1 Biomarker for Response DAKO 22C3 - MediPaper Medical Communications

PD-L1 Biomarker: a Comparison of ASCO2016 PD-1 and PD-L1 Data

There is no excerpt because this is a protected post.

ESMO 2016 durvalumab avelumab tremelimumab data medipaper medical communications

ESMO16 Durvalumab, Avelumab, Tremelimumab Data - Download the PPT

There is no excerpt because this is a protected post.

ESMO 2016 atezolizumab data medipaper medical communications

ESMO16 Atezolizumab data - Download the PPT

There is no excerpt because this is a protected post.

ESMO 2016 nivolumab data medipaper medical communications

ESMO16 Nivolumab data - Download the PPT

There is no excerpt because this is a protected post.

ASCO 2016 Avelumab Durvalumab and Tremelimumab Data - MediPaper Medical Communications

ASCO16 Avelumab, Durvalumab, and Tremelimumab

There is no excerpt because this is a protected post.

asco 2016 atezolizumab data

ASCO16 Atezolizumab (Tecentriq©) Data

There is no excerpt because this is a protected post.